JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 928.07 Billion KRW | 7.35% |
| 2022 | 864.53 Billion KRW | 9.58% |
| 2021 | 788.93 Billion KRW | 0.95% |
| 2020 | 781.51 Billion KRW | 7.58% |
| 2019 | 726.42 Billion KRW | 0.15% |
| 2018 | 725.36 Billion KRW | 6.09% |
| 2017 | 683.71 Billion KRW | 0.48% |
| 2016 | 680.47 Billion KRW | 9.29% |
| 2015 | 622.61 Billion KRW | 8.48% |
| 2014 | 573.92 Billion KRW | 8.23% |
| 2013 | 530.26 Billion KRW | 3.58% |
| 2012 | 511.94 Billion KRW | -0.79% |
| 2011 | 516.01 Billion KRW | -6.9% |
| 2010 | 554.23 Billion KRW | -0.44% |
| 2009 | 556.67 Billion KRW | 5.18% |
| 2008 | 529.23 Billion KRW | 122.66% |
| 2007 | 237.69 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 214.73 Billion KRW | -3.7% |
| 2024 Q1 | 222.98 Billion KRW | -14.74% |
| 2023 Q1 | 216.39 Billion KRW | -10.17% |
| 2023 Q3 | 216.5 Billion KRW | -7.34% |
| 2023 FY | 928.07 Billion KRW | 7.35% |
| 2023 Q4 | 261.52 Billion KRW | 20.79% |
| 2023 Q2 | 233.65 Billion KRW | 7.98% |
| 2022 Q4 | 240.9 Billion KRW | 10.77% |
| 2022 Q2 | 205.25 Billion KRW | 2.17% |
| 2022 FY | 864.53 Billion KRW | 9.58% |
| 2022 Q1 | 200.9 Billion KRW | -13.16% |
| 2022 Q3 | 217.47 Billion KRW | 5.95% |
| 2021 Q4 | 231.35 Billion KRW | 30.06% |
| 2021 FY | 788.93 Billion KRW | 0.95% |
| 2021 Q1 | 189.56 Billion KRW | -5.79% |
| 2021 Q2 | 190.13 Billion KRW | 0.3% |
| 2021 Q3 | 177.87 Billion KRW | -6.45% |
| 2020 Q2 | 193.07 Billion KRW | 3.12% |
| 2020 Q1 | 187.22 Billion KRW | 9.17% |
| 2020 FY | 781.51 Billion KRW | 7.58% |
| 2020 Q4 | 201.21 Billion KRW | 0.61% |
| 2020 Q3 | 200 Billion KRW | 3.59% |
| 2019 Q4 | 171.49 Billion KRW | -10.0% |
| 2019 Q3 | 190.54 Billion KRW | 2.22% |
| 2019 Q2 | 186.4 Billion KRW | 4.73% |
| 2019 Q1 | 177.98 Billion KRW | 2.33% |
| 2019 FY | 726.42 Billion KRW | 0.15% |
| 2018 Q4 | 173.93 Billion KRW | -10.51% |
| 2018 Q1 | 180.75 Billion KRW | 23.27% |
| 2018 FY | 725.36 Billion KRW | 6.09% |
| 2018 Q2 | 176.31 Billion KRW | -2.46% |
| 2018 Q3 | 194.35 Billion KRW | 10.24% |
| 2017 Q3 | 180.05 Billion KRW | 3.92% |
| 2017 FY | 683.71 Billion KRW | 0.48% |
| 2017 Q4 | 146.64 Billion KRW | -18.56% |
| 2017 Q1 | 183.75 Billion KRW | 17.16% |
| 2017 Q2 | 173.26 Billion KRW | -5.71% |
| 2016 Q1 | 171.58 Billion KRW | 10.78% |
| 2016 Q2 | 176.81 Billion KRW | 3.04% |
| 2016 Q3 | 175.23 Billion KRW | -0.89% |
| 2016 FY | 680.47 Billion KRW | 9.29% |
| 2016 Q4 | 156.84 Billion KRW | -10.5% |
| 2015 FY | 622.61 Billion KRW | 8.48% |
| 2015 Q4 | 154.89 Billion KRW | -3.6% |
| 2015 Q2 | 161.18 Billion KRW | 10.93% |
| 2015 Q1 | 145.29 Billion KRW | -11.62% |
| 2015 Q3 | 160.67 Billion KRW | -0.31% |
| 2014 Q3 | 140.83 Billion KRW | -0.86% |
| 2014 Q2 | 142.06 Billion KRW | 12.65% |
| 2014 Q1 | 126.11 Billion KRW | -2.46% |
| 2014 FY | 573.92 Billion KRW | 8.23% |
| 2014 Q4 | 164.4 Billion KRW | 16.73% |
| 2013 Q1 | 129.48 Billion KRW | -10.61% |
| 2013 Q3 | 133.52 Billion KRW | -3.23% |
| 2013 Q4 | 129.28 Billion KRW | -3.17% |
| 2013 FY | 530.26 Billion KRW | 3.58% |
| 2013 Q2 | 137.98 Billion KRW | 6.56% |
| 2012 Q4 | 144.85 Billion KRW | 8.22% |
| 2012 Q2 | 126.19 Billion KRW | 19.18% |
| 2012 Q1 | 105.88 Billion KRW | 0.0% |
| 2012 FY | 511.94 Billion KRW | -0.79% |
| 2012 Q3 | 133.84 Billion KRW | 6.06% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 516.01 Billion KRW | -6.9% |
| 2011 Q2 | 11.63 Billion KRW | -9.29% |
| 2011 Q1 | 12.83 Billion KRW | 0.0% |
| 2011 Q3 | 10.6 Billion KRW | -8.88% |
| 2010 Q3 | 16.08 Billion KRW | -2.99% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 554.23 Billion KRW | -0.44% |
| 2010 Q2 | 16.58 Billion KRW | 8.87% |
| 2010 Q1 | 15.23 Billion KRW | 0.0% |
| 2009 FY | 556.67 Billion KRW | 5.18% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 15.99 Billion KRW | 7.94% |
| 2009 Q2 | 14.81 Billion KRW | 23.74% |
| 2009 Q1 | 11.97 Billion KRW | 0.0% |
| 2008 FY | 529.23 Billion KRW | 122.66% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 9.18 Billion KRW | 6.55% |
| 2008 Q3 | 9.56 Billion KRW | 4.1% |
| 2008 Q1 | 8.62 Billion KRW | 0.0% |
| 2007 FY | 237.69 Billion KRW | 0.0% |
| 2007 Q3 | 6.94 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -576.39% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 18.015% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -45.364% |
| HANDOK Inc. | 522.74 Billion KRW | -77.539% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -585.568% |
| Yuhan Corporation | 1858.98 Billion KRW | 50.076% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -39.774% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1686.298% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 37.75% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -587.92% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -150.466% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -947.561% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -447.317% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -313.474% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -576.39% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1089.024% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -514.328% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -962.309% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -54.483% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 44.407% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -23.986% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -363.506% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -413.42% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -372.672% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -27.764% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -576.39% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 38.719% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 32.52% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -23.986% |
| Yuhan Corporation | 1858.98 Billion KRW | 50.076% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -16.781% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -295.088% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -56.092% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -23.986% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -217.693% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -232.71% |
| CKD Bio Corp. | 160.35 Billion KRW | -478.769% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -76.121% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -157.006% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -302.82% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -363.506% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -5.489% |
| Boryung Corporation | 859.62 Billion KRW | -7.962% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -636.985% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -150.466% |
| JW Lifescience Corporation | 206.86 Billion KRW | -348.646% |